% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{MacherGoeppinger:119276,
      author       = {S. Macher-Goeppinger$^*$ and M. Keith$^*$ and V. Endris and
                      R. Penzel and K. Tagscherer$^*$ and S. Pahernik and M.
                      Hohenfellner and H. Gardner and C. Grüllich and P.
                      Schirmacher and W. Roth$^*$},
      title        = {{MET} expression and copy number status in clear-cell renal
                      cell carcinoma: prognostic value and potential predictive
                      marker.},
      journal      = {OncoTarget},
      volume       = {8},
      number       = {1},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2017-00062},
      pages        = {1046-1057},
      year         = {2017},
      abstract     = {Multiple targeted therapy for advanced clear-cell renal
                      cell carcinoma (RCC) has substantially improved patient
                      outcome, but complete remission is uncommon and many tumors
                      eventually develop resistance. Mechanistic, preclinical, and
                      early clinical data highlight c-Met / hepatocyte growth
                      factor receptor as a promising target for RCC therapeutic
                      agents.We have examined MET expression, frequency of MET
                      gene copy gains and MET gene mutation in a large,
                      hospital-based series of renal cell carcinomas with
                      long-term follow-up information.Out of a total of 572
                      clear-cell RCC, only $17\%$ were negative for MET expression
                      whereas $32\%$ showed high protein levels. High MET
                      expression and MET copy number gains were associated with an
                      aggressive phenotype and an unfavorable patient outcome.
                      Elevated protein levels in absence of gene amplification
                      were not attributed to mutations, based on results of
                      targeted next-generation sequencing.Our data reveal that
                      clear-cell RCC with MET upregulation show an aggressive
                      behavior and MET copy number increase is evident in a
                      substantial percentage of patients with high-grade
                      carcinomas and metastatic disease. Diagnostic assessment of
                      MET expression and amplification may be of predictive value
                      to guide targeted therapy against MET signaling in patients
                      with clear-cell RCC.},
      cin          = {G150},
      ddc          = {610},
      cid          = {I:(DE-He78)G150-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27894094},
      doi          = {10.18632/oncotarget.13540},
      url          = {https://inrepo02.dkfz.de/record/119276},
}